Aquestive Therapeutics, Inc.
AQST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001398733
In the last 90 days, Aquestive Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 185 institutions reported holding it in 13F filings for Q2 2026, worth $299.5M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Aquestive Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 35 | 54 | +19 |
| Shares | 14.9M | 19.1M | +4.14M (+27.7%) |
| Value | $17.0M | $31.5M | +$14.5M (+84.9%) |
New holders (24)
Institutions that held Aquestive Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (5)
Institutions that held Aquestive Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Kestra Advisory Services, LLC | 86,350 | $98.4K |
| Jane Street Group, LLC | 23,430 | $26.7K |
| Virtu Financial LLC | 12,884 | $15.0K |
| UBS Group AG | 3,744 | $4.27K |
| TCI Wealth Advisors, Inc. | 500 | $570 |